Treatment of B Cell Lymphomas with Synthetic Peptides

The long term goal of this project is the development of synthetic peptide-based therapy for Humanlymphomas. The phase I period will serve (1) to test the feasibility of identifying peptide ligandsimmunoglobulin antigen receptors (IgR) from patients' tumors; and (2) to test the in vivo efficacy oligands in the SUP- B8 SCID mouse model system. The specific tasks to be accomplished are to 1) isolfrom culture supernatant of hybridomas previously established from patient lymphoma biopsies; 2) scrrandom peptide libraries against each immunoglobulin preparation to find specific peptide ligands. (peptides 8 to 20 residues in length expressed on the pIII and pVIII coat proteins of filamentous phacomplexed with plasmids, or displayed as nascent peptides in polysomes.); 3) synthesize, purify, andof the peptide ligands; 4) characterize the specificities, affinities, and biological activities ofefficacy of the synthetic peptides in SCID mouse model by treating mice bearing the human tumor withadministration protocols.